This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TearLab Corp. operates as an ophthalmic device company in the United States. It develops and markets lab-on-a-chip technologies that enable eye care practitioners to enhance standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care.View TEAR
TearLab Corp - TEAR - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates TearLab Corp as a
Sell with a ratings score of D-.
Report Snippet: We rate TEARLAB CORP (TEAR) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.